Xarelto (Rivaroxaban) Patent Expiration, LOE Window & CMS Spending
Xarelto (Rivaroxaban) by Johnson & Johnson: FDA Orange Book LOE 2034-08-17, 18 AB generics, $6.74B 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N022406 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2034-08-17 |
| Orange Book Patents (*PED Extensions) | 2 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 18 |
| 2024 CMS Total Public Spend | $6.74B |
| 2024 Medicare Part D Spend | $6.23B |
| 2024 Medicaid Spend | $506.8M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.